Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells

Mariko Muta, Tomonori Yanagawa, Yoshimichi Sai, Shigehira Saji, Eiji Suzuki, Tomoyuki Aruga, Katsumasa Kuroi, Gaku Matsumoto, Masakazu Toi, Emi Nakashima

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: Bone marrow (BM)-derived endothelial progenitor cells (EPC) play an important role in neovascularization and tumor growth. It has been reported that docetaxel and paclitaxel inhibit angiogenesis, but the effect of docetaxel and paclitaxel on EPC-induced neovascularization has not been examined. We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC. Methods: The effects of drugs on growth, tube formation, and migration of EPC were analyzed in vitro using a rat BM-derived EPC cell line (TR-BME). Fluorescence-labeled TR-BME cells were injected into tumor-bearing rats and accumulation at the tumor site was analyzed by fluorescence-activated cell sorting (FACS). Results: In in vitro cytotoxicity assays of these drugs in TR-BME, rat endothelial cell line TR-BBB and rat tumor cell line Walker 256, the IC50 values for TR-BME were higher than those for TR-BBB or Walker 256. Both drugs inhibited tube formation and migration of TR-BME at lower concentrations than the cytotoxic IC50. In vivo studies showed that a low dose of both drugs inhibited EPC accumulation at the tumor site in tumor-bearing rats, as determined by FACS, and caused a decrease in microvessel density. Conclusion: Docetaxel and paclitaxel directly inhibited EPC-initiated vasculogenesis at low (non-cytotoxic) concentrations, causing suppression of tumor growth.

Original languageEnglish
Pages (from-to)182-191
Number of pages10
JournalOncology
Volume77
Issue number3-4
DOIs
Publication statusPublished - 2009 Sep

Fingerprint

docetaxel
Paclitaxel
Neoplasms
Pharmaceutical Preparations
Inhibitory Concentration 50
Flow Cytometry
Growth
Bone Marrow
Cell Line
Angiogenesis Inducing Agents
Microvessels
Endothelial Progenitor Cells
Tumor Cell Line
Endothelial Cells
Fluorescence

Keywords

  • Docetaxel
  • Endothelial progenitor cells
  • Neovascularization
  • Paclitaxel
  • Vasculogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Muta, M., Yanagawa, T., Sai, Y., Saji, S., Suzuki, E., Aruga, T., ... Nakashima, E. (2009). Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells. Oncology, 77(3-4), 182-191. https://doi.org/10.1159/000236016

Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells. / Muta, Mariko; Yanagawa, Tomonori; Sai, Yoshimichi; Saji, Shigehira; Suzuki, Eiji; Aruga, Tomoyuki; Kuroi, Katsumasa; Matsumoto, Gaku; Toi, Masakazu; Nakashima, Emi.

In: Oncology, Vol. 77, No. 3-4, 09.2009, p. 182-191.

Research output: Contribution to journalArticle

Muta, M, Yanagawa, T, Sai, Y, Saji, S, Suzuki, E, Aruga, T, Kuroi, K, Matsumoto, G, Toi, M & Nakashima, E 2009, 'Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells', Oncology, vol. 77, no. 3-4, pp. 182-191. https://doi.org/10.1159/000236016
Muta M, Yanagawa T, Sai Y, Saji S, Suzuki E, Aruga T et al. Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells. Oncology. 2009 Sep;77(3-4):182-191. https://doi.org/10.1159/000236016
Muta, Mariko ; Yanagawa, Tomonori ; Sai, Yoshimichi ; Saji, Shigehira ; Suzuki, Eiji ; Aruga, Tomoyuki ; Kuroi, Katsumasa ; Matsumoto, Gaku ; Toi, Masakazu ; Nakashima, Emi. / Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells. In: Oncology. 2009 ; Vol. 77, No. 3-4. pp. 182-191.
@article{6c6223739bd54b419acb4ef017a61a40,
title = "Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells",
abstract = "Objective: Bone marrow (BM)-derived endothelial progenitor cells (EPC) play an important role in neovascularization and tumor growth. It has been reported that docetaxel and paclitaxel inhibit angiogenesis, but the effect of docetaxel and paclitaxel on EPC-induced neovascularization has not been examined. We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC. Methods: The effects of drugs on growth, tube formation, and migration of EPC were analyzed in vitro using a rat BM-derived EPC cell line (TR-BME). Fluorescence-labeled TR-BME cells were injected into tumor-bearing rats and accumulation at the tumor site was analyzed by fluorescence-activated cell sorting (FACS). Results: In in vitro cytotoxicity assays of these drugs in TR-BME, rat endothelial cell line TR-BBB and rat tumor cell line Walker 256, the IC50 values for TR-BME were higher than those for TR-BBB or Walker 256. Both drugs inhibited tube formation and migration of TR-BME at lower concentrations than the cytotoxic IC50. In vivo studies showed that a low dose of both drugs inhibited EPC accumulation at the tumor site in tumor-bearing rats, as determined by FACS, and caused a decrease in microvessel density. Conclusion: Docetaxel and paclitaxel directly inhibited EPC-initiated vasculogenesis at low (non-cytotoxic) concentrations, causing suppression of tumor growth.",
keywords = "Docetaxel, Endothelial progenitor cells, Neovascularization, Paclitaxel, Vasculogenesis",
author = "Mariko Muta and Tomonori Yanagawa and Yoshimichi Sai and Shigehira Saji and Eiji Suzuki and Tomoyuki Aruga and Katsumasa Kuroi and Gaku Matsumoto and Masakazu Toi and Emi Nakashima",
year = "2009",
month = "9",
doi = "10.1159/000236016",
language = "English",
volume = "77",
pages = "182--191",
journal = "Oncology (Switzerland)",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells

AU - Muta, Mariko

AU - Yanagawa, Tomonori

AU - Sai, Yoshimichi

AU - Saji, Shigehira

AU - Suzuki, Eiji

AU - Aruga, Tomoyuki

AU - Kuroi, Katsumasa

AU - Matsumoto, Gaku

AU - Toi, Masakazu

AU - Nakashima, Emi

PY - 2009/9

Y1 - 2009/9

N2 - Objective: Bone marrow (BM)-derived endothelial progenitor cells (EPC) play an important role in neovascularization and tumor growth. It has been reported that docetaxel and paclitaxel inhibit angiogenesis, but the effect of docetaxel and paclitaxel on EPC-induced neovascularization has not been examined. We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC. Methods: The effects of drugs on growth, tube formation, and migration of EPC were analyzed in vitro using a rat BM-derived EPC cell line (TR-BME). Fluorescence-labeled TR-BME cells were injected into tumor-bearing rats and accumulation at the tumor site was analyzed by fluorescence-activated cell sorting (FACS). Results: In in vitro cytotoxicity assays of these drugs in TR-BME, rat endothelial cell line TR-BBB and rat tumor cell line Walker 256, the IC50 values for TR-BME were higher than those for TR-BBB or Walker 256. Both drugs inhibited tube formation and migration of TR-BME at lower concentrations than the cytotoxic IC50. In vivo studies showed that a low dose of both drugs inhibited EPC accumulation at the tumor site in tumor-bearing rats, as determined by FACS, and caused a decrease in microvessel density. Conclusion: Docetaxel and paclitaxel directly inhibited EPC-initiated vasculogenesis at low (non-cytotoxic) concentrations, causing suppression of tumor growth.

AB - Objective: Bone marrow (BM)-derived endothelial progenitor cells (EPC) play an important role in neovascularization and tumor growth. It has been reported that docetaxel and paclitaxel inhibit angiogenesis, but the effect of docetaxel and paclitaxel on EPC-induced neovascularization has not been examined. We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC. Methods: The effects of drugs on growth, tube formation, and migration of EPC were analyzed in vitro using a rat BM-derived EPC cell line (TR-BME). Fluorescence-labeled TR-BME cells were injected into tumor-bearing rats and accumulation at the tumor site was analyzed by fluorescence-activated cell sorting (FACS). Results: In in vitro cytotoxicity assays of these drugs in TR-BME, rat endothelial cell line TR-BBB and rat tumor cell line Walker 256, the IC50 values for TR-BME were higher than those for TR-BBB or Walker 256. Both drugs inhibited tube formation and migration of TR-BME at lower concentrations than the cytotoxic IC50. In vivo studies showed that a low dose of both drugs inhibited EPC accumulation at the tumor site in tumor-bearing rats, as determined by FACS, and caused a decrease in microvessel density. Conclusion: Docetaxel and paclitaxel directly inhibited EPC-initiated vasculogenesis at low (non-cytotoxic) concentrations, causing suppression of tumor growth.

KW - Docetaxel

KW - Endothelial progenitor cells

KW - Neovascularization

KW - Paclitaxel

KW - Vasculogenesis

UR - http://www.scopus.com/inward/record.url?scp=69549125966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549125966&partnerID=8YFLogxK

U2 - 10.1159/000236016

DO - 10.1159/000236016

M3 - Article

C2 - 19729975

AN - SCOPUS:69549125966

VL - 77

SP - 182

EP - 191

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - 3-4

ER -